Last edition
News about "WuXi Biologics"
Earendil Labs and WuXi Biologics Partner on Bispecific Antibodies and ADCs
Under the agreement, WuXi Biologics will provide end-to-end development and manufacturing services to Earendil Labs, supporting faster regulatory timelines, reliable CMC execution, and scalable global clinical development.
WuXi Biologics | 13/03/2026 | By News Bureau
WuXi Biologics and Vertex Pharmaceuticals collaborate to advance a preclinical trispecific T-cell engager targeting B-cell mediated autoimmune diseases under a global licensing agreement.
WuXi Biologics | 03/02/2026 | By News Bureau | 158
WuXi Biologics, Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases
WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development of SND006, a novel bispecific antibody targeting inflammatory bowel disease and autoimmune disorders.
WuXi Biologics | 29/01/2026 | By News Bureau | 145
WuXi Biologics Introduces PatroLab to Enable Real-Time, Predictive Biomanufacturing
WuXi Biologics, a global contract research, development and manufacturing organization (CRDMO), has launched PatroLab, a next-generation digital twin platform aimed at reshaping bioprocess development and biologics manufacturing.
WuXi Biologics | 14/01/2026 | By Darshana | 352
WuXi Biologics' Wuxi Facilities Receive MHRA GMP Approval for Ophthalmic Biologic Manufacturing
The UK regulator has certified WuXi Biologics’ DP5 and DPPC sites in Wuxi for commercial production, reinforcing the company’s global GMP-compliant manufacturing capabilities.
WuXi Biologics | 13/01/2026 | By News Bureau | 211
WuXi Biologics, a global contract research, development and manufacturing organisation (CRDMO), has achieved ISO 20400 Sustainable Procurement certification, a globally recognised standard that embeds sustainability principles into procurement practices and promotes transparency, accountability and responsible supply chain management.
WuXi Biologics | 06/01/2026 | By Darshana | 136
WuXi Biologics Extends CRDMO Footprint to Qatar
WuXi Biologics has signed an MoU with the Qatar Free Zones Authority (QFZ) to expand its global footprint into the Middle East. The partnership sets the stage for the company’s first integrated CRDMO centre in the region, strengthening its worldwide research, development, and manufacturing capabilities.
WuXi Biologics | 02/12/2025 | By Dineshwori | 308
WuXi Biologics, a leading global contract research, development and manufacturing organisation (CRDMO), has announced that its Dundalk, Ireland facility has been approved by the European Medicines Agency (EMA) as a commercial manufacturing site for a client’s innovative biologic.
WuXi Biologics | 18/08/2025 | By Dineshwori | 224
WuXi Biologics Completes First Commercial PPQ Campaign at MFG20 Hangzhou Facility
WuXi Biologics completes the first commercial project Process Performance Qualification (PPQ) campaign for its three sets of 5,000L single-use bioreactors (SUBs).
WuXi Biologics | 19/04/2025 | By Abha | 243
WuXi Biologics Signs Deal with Candid Therapeutics to Boost Trispecific T-cell Engager
Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal multispecific antibody platform WuXiBody.
WuXi Biologics | 07/01/2025 | By Aishwarya | 416
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy